Testosterone supplementation and body composition: results from a meta-analysis of observational studies
The concept of testosterone (T) supplementation (TS) as a new anti-obesity medication in men with testosterone deficiency syndrome (TDS) is emerging. Data from placebo-controlled trials are more conflicting. The aim of this study is to systematically review and meta-analyze available observational and register studies reporting data on body composition in studies on TS in TDS.
An extensive MEDLINE, Embase, and Cochrane search was performed including the following words: “testosterone” and “body composition.” All observational studies comparing the effect of TS on body weight and other body composition and metabolic endpoints were considered.
Out of 824 retrieved articles, 32 were included in the study enrolling 4513 patients (mean age 51.7 ± 6.1 years). TS was associated with a time-dependent reduction in body weight and waist circumference (WC). The estimated weight loss and WC reduction at 24 months were −3.50 [−5.21; −1.80] kg and −6.23 [−7.94; −4.76] cm, respectively. TS was also associated with a significant reduction in fat and with an increase in lean mass as well as with a reduction in fasting glycemia and insulin resistance. In addition, an improvement of lipid profile (reduction in total cholesterol as well as of triglyceride levels and an improvement in HDL cholesterol levels) and in both systolic and diastolic blood pressure was observed.
Present data support the view of a positive effect of TS on body composition and on glucose and lipid metabolism. In addition, a significant effect on body weight loss was observed, which should be confirmed by a specifically designed RCT.
KeywordsTestosterone Weight loss Body composition Obesity diabetes Hypogonadism
Compliance with Ethical Standards
Conflict of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the review.
This article does not contain any studies with human participants or animals performed by any of the authors.
Since this is a meta-analysis informed consent is not applicable.
- 21.Zitzmann M, Saad F, Kliesch S (2014) Long-term treatment with testosterone undecanoate injections leads to sustained weight loss and improvement of metabolic syndrome parameters in 381 hypogonadal men. J Sex Med 11(Suppl. 1):7Google Scholar
- 32.Rebuffé-Scrive M, Mårin P, Björntorp P (1991) Effect of testosterone on abdominal adipose tissue in men. Int J Obes 15:791–795Google Scholar
- 37.Wang C, Eyre DR, Clark R, Kleinberg D, Newman C, Iranmanesh A et al (1996) Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab 81:3654–3662PubMedGoogle Scholar
- 41.Brill KT, Weltman AL, Gentili A, Patrie JT, Fryburg DA, Hanks JB et al (2002) Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab 87:5649–5657CrossRefPubMedGoogle Scholar
- 54.Tirabassi G, Delli Muti N, Corona G, Maggi M, Balercia G (2013) Androgen receptor gene CAG repeat polymorphism regulates the metabolic effects of testosterone replacement therapy in male postsurgical hypogonadotropic hypogonadism. Int J Endocrinol. 2013:816740CrossRefPubMedPubMedCentralGoogle Scholar
- 62.Wu XY, Mao JF, Lu SY, Zhang Q, Shi YF (2009) Testosterone replacement therapy improves insulin sensitivity and decreases high sensitivity C-reactive protein levels in hypogonadotropic hypogonadal young male patients. Chin Med J (Engl) 122:2846–2850Google Scholar
- 63.Cochrane Handbook for Systematic Reviews of Interventions. Available at http://www.cochrane-handbook.org. Last accessed 26 Dec 2015
- 66.Cohen J (1977) Statistical power analysis for the behavioral sciences. Academic Press, New YorkGoogle Scholar
- 69.Sgrò P, Romanelli F, Felici F, Sansone M, Bianchini S, Buzzachera CF, Baldari C, Guidetti L, Pigozzi F, Lenzi A, Di Luigi L (2014) Testosterone responses to standardized short-term sub-maximal and maximal endurance exercises: issues on the dynamic adaptive role of the hypothalamic-pituitary-testicular axis. J Endocrinol Investig 37:13–24CrossRefGoogle Scholar
- 71.Corona G, Rastrelli G, Maggi M (2015) The pharmacotherapy of male hypogonadism besides androgens. Expert Opin Pharmacother 16:369–487. Erratum in: Expert Opin Pharmacother. 2015;16:941. Ratrelli, Giulia [corrected to Rastrelli, Giulia]Google Scholar
- 73.Rastrelli G, Giovannini L, Calogero AE, Gianfrilli D, Serra E, Pizzocaro A, Giagulli VA, Motta G, Vancieri G, Sperandio A, Andò S, Selice R, Luca G, Cocchiara F, Canale D, Maggi M (2016) Predictors and clinical consequences of starting androgen therapy in men with low testosterone: results from the SIAMO-NOI registry. J Endocrinol Invest 39(6):695–708CrossRefPubMedGoogle Scholar